Gene subnetworks provide new prognostic markers for breast cancer
The 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE), the largest and most comprehensive ophthalmic educational meeting in the world, is in session November 8 to 11 at the Georgia World Congress Center, Atlanta. Offerings include 277 continuing medical education courses, 179 ” Breakfast with the Experts
Full Post: Advances in ophthalmology
The metastasis or spread of breast cancer to other tissues in the body can be predicted more accurately by examining subnetworks of gene expression patterns in a patient’s tumor, than by conventional gene expression microarrays, according to a presentation at the American Society for Cell Biology (ASCB) 48th Annual Meeting, Dec. 13-17, 2008 in San Francisco.
The subnetworks provide new prognostic markers representing sets of co-functional genes, say scientists at the University of California at San Diego (UCSD), Trey Ideker and Han-Yu Chuang, who worked with Eunjung Lee and Doehaon Lee of the Korean Advanced Institute of Science and Technology in Daejeon, South Korea.
The U.S.-Korea researchers identified the subnetworks by using bioinformatic algorithms to crunch through mountains of gene expression profiles from large cohorts of women with breast cancer.
The data represented women with breast cancer metastasis as well as patients whose tumors had not spread.
The gene expression profiles were then mapped to the extensive networks of signaling pathways and protein complexes in human cells that had been revealed in previous studies.
Searching the data, the researchers identified subnetworks in which aggregate gene expression patterns distinguished one patient group from another.
They also uncovered many genes associated with breast cancer that had not been identified by previous gene microarray profiles.
Thanks to rapid microarray technology, cancers can now be classified according to their gene expression, or activity patterns.
However, disease classification by gene expression is imprecise because cells taken from a single tumor sample often are heterogeneous; genes switched on in cells from one part of the tumor may not be active elsewhere in the tumor.
In addition, the expression profiles from a range of patients with the “same” type and grade of tumor can differ significantly.
Ideker and Chuang’s approach may change diagnostics so that a patient’s diagnosis could go beyond, for example, estrogen responsive breast cancer to a particular subtype of estrogen responsive breast cancer with poor or good prognosis.
The U.S.-Korean researchers are now extending their new integrated analysis to other cancers including leukemia, prostate cancer and lung cancer.
They are identifying “condition-responsive” genes within signaling and transcriptional pathways that could be used as a measure of activation levels and could provide another useful tool for diagnosis and prognosis, they say.
New research in mice and five independent collections of human breast tumors has enabled National Cancer Institute (NCI) scientists to confirm that genes for factors contributing to susceptibility for breast cancer metastasis can be inherited. The new findings support earlier results from the same laboratory and appear in the Jan. 1, 2009, issue of Cancer
Full Post: Inherited factors play key role in breast cancer
Rather than testing for individual marker genes or proteins, researchers at the University of California, San Diego (UC San Diego) and the Moores UCSD Cancer Center have evidence that groups, or networks, of interactive genes may be more reliable in determining the likelihood that a form of leukemia is fast-moving or slow-growing. One of the
Full Post: Networks of interactive genes may predict Leukemia’s development
A new study reveals that the metadherin gene (MTDH) plays a role in both cancer metastasis and resistance to chemotherapy. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell , identifies MTDH as a promising therapeutic target for high risk breast cancers. “Most breast cancer patients resist currently
Full Post: Metadherin gene plays dual role in breast cancers with poor prognosis
Cancer researchers at the Max Delbr?nter for Molecular Medicine (MDC) Berlin-Buch and the Charité - Universit? Medizin Berlin (Germany) have identified a gene which enables them to predict for the first time with high probability if colon cancer is going to metastasize. Assistant Professor Dr. Ulrike Stein, Professor Peter M. Schlag, and Professor Walter Birchmeier
Full Post: Scientists find gene that is a powerful predictor of colon cancer metastasis
A team of researchers at Princeton University and The Cancer Institute of New Jersey has identified a long-sought gene that is fatefully switched on in 30 to 40 percent of all breast cancer patients, spreading the disease, resisting traditional chemotherapies and eventually leading to death. The gene, called “Metadherin” or MTDH, is located in a
Full Post: Metadherin gene linked to metastasis of breast cancer